NZ702721A - Vaccination with interleukin-4 antagonists - Google Patents
Vaccination with interleukin-4 antagonistsInfo
- Publication number
- NZ702721A NZ702721A NZ702721A NZ70272113A NZ702721A NZ 702721 A NZ702721 A NZ 702721A NZ 702721 A NZ702721 A NZ 702721A NZ 70272113 A NZ70272113 A NZ 70272113A NZ 702721 A NZ702721 A NZ 702721A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antigen
- interleukin
- subject
- dose
- compositions
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000004388 Interleukin-4 Human genes 0.000 title 1
- 108090000978 Interleukin-4 Proteins 0.000 title 1
- 229940028885 interleukin-4 Drugs 0.000 title 1
- 238000002255 vaccination Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 229940123418 Interleukin 4 receptor antagonist Drugs 0.000 abstract 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000037452 priming Effects 0.000 abstract 2
- 101710177291 Gag polyprotein Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 102100034353 Integrase Human genes 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 108010078428 env Gene Products Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 108010089520 pol Gene Products Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902345A AU2012902345A0 (en) | 2012-06-05 | Vaccination with Interleukin-4 Antagonists | |
| PCT/AU2013/000589 WO2013181696A1 (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ702721A true NZ702721A (en) | 2016-11-25 |
Family
ID=49711200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ702721A NZ702721A (en) | 2012-06-05 | 2013-06-05 | Vaccination with interleukin-4 antagonists |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20150150963A1 (https=) |
| EP (2) | EP3530283A1 (https=) |
| JP (1) | JP2015520175A (https=) |
| KR (1) | KR20150021088A (https=) |
| CN (1) | CN104717971A (https=) |
| AU (1) | AU2013271338B2 (https=) |
| BR (1) | BR112014030436A2 (https=) |
| CA (1) | CA2875683A1 (https=) |
| HK (1) | HK1203358A1 (https=) |
| IL (1) | IL236092A0 (https=) |
| IN (1) | IN2014DN10408A (https=) |
| NZ (1) | NZ702721A (https=) |
| SG (1) | SG11201408101TA (https=) |
| WO (1) | WO2013181696A1 (https=) |
| ZA (1) | ZA201409076B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017220184B2 (en) * | 2016-02-19 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist |
| CN113527485B (zh) * | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| JP3282188B2 (ja) | 1991-06-27 | 2002-05-13 | 日本電気株式会社 | 半導体メモリ装置 |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU691175B2 (en) | 1993-03-31 | 1998-05-14 | Nippon Zeon Co., Ltd. | Novel polypeptide, DNA coding for said polypeptide, recombinant vector containing said DNA, recombinant virus prepared using said vector, and use thereof |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| DK0690732T3 (da) | 1994-01-21 | 2003-05-19 | Powderject Vaccines Inc | Gasdrevet genindførselsinstrument |
| GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
| US6265387B1 (en) | 1995-10-11 | 2001-07-24 | Mirus, Inc. | Process of delivering naked DNA into a hepatocyte via bile duct |
| US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| NZ505325A (en) | 1997-12-23 | 2003-07-25 | Crucell Holland B | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
| US6972013B1 (en) | 1998-07-13 | 2005-12-06 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
| US7608273B2 (en) | 1998-08-12 | 2009-10-27 | University Of Western Ontario | Recombinant lentivirus encoding modified GP 120 signal sequences |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
| ATE528406T1 (de) | 1999-04-29 | 2011-10-15 | Gbp Ip Llc | Verfahren und mittel zur herstellung von sicheren,rekombinanten lentivirusvektoren mit hohem titer |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| AU2001257611A1 (en) | 2000-04-28 | 2001-11-12 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
| ATE315660T1 (de) | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| AU2003263653A1 (en) | 2002-09-27 | 2004-04-19 | Daewoong Co., Ltd. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
| US8287879B2 (en) * | 2003-10-16 | 2012-10-16 | The Regents Of The University Of California | Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US7541046B1 (en) | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US8048404B1 (en) | 2005-01-04 | 2011-11-01 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles for protein drug delivery |
| CA2605924A1 (en) | 2005-04-24 | 2006-11-02 | Acambis Inc. | Recombinant flavivirus vaccines |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| JP2009525267A (ja) * | 2006-01-11 | 2009-07-09 | アエロヴァンス インコーポレイティッド | ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物 |
| AR066240A1 (es) * | 2007-04-23 | 2009-08-05 | Wyeth Corp | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 |
| US20120088814A1 (en) * | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
| WO2011003138A1 (en) * | 2009-07-06 | 2011-01-13 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
-
2013
- 2013-06-05 EP EP19150395.2A patent/EP3530283A1/en not_active Withdrawn
- 2013-06-05 US US14/405,704 patent/US20150150963A1/en not_active Abandoned
- 2013-06-05 JP JP2015515352A patent/JP2015520175A/ja active Pending
- 2013-06-05 IN IN10408DEN2014 patent/IN2014DN10408A/en unknown
- 2013-06-05 KR KR20147037109A patent/KR20150021088A/ko not_active Withdrawn
- 2013-06-05 CA CA2875683A patent/CA2875683A1/en not_active Abandoned
- 2013-06-05 BR BR112014030436A patent/BR112014030436A2/pt not_active IP Right Cessation
- 2013-06-05 AU AU2013271338A patent/AU2013271338B2/en not_active Ceased
- 2013-06-05 NZ NZ702721A patent/NZ702721A/en not_active IP Right Cessation
- 2013-06-05 EP EP13800233.2A patent/EP2854837A4/en not_active Withdrawn
- 2013-06-05 HK HK15103819.6A patent/HK1203358A1/xx unknown
- 2013-06-05 CN CN201380040156.6A patent/CN104717971A/zh active Pending
- 2013-06-05 WO PCT/AU2013/000589 patent/WO2013181696A1/en not_active Ceased
- 2013-06-05 SG SG11201408101TA patent/SG11201408101TA/en unknown
-
2014
- 2014-12-04 IL IL236092A patent/IL236092A0/en unknown
- 2014-12-10 ZA ZA2014/09076A patent/ZA201409076B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2875683A1 (en) | 2013-12-12 |
| US20150150963A1 (en) | 2015-06-04 |
| HK1203358A1 (en) | 2015-10-30 |
| IN2014DN10408A (https=) | 2015-08-14 |
| CN104717971A (zh) | 2015-06-17 |
| AU2013271338A1 (en) | 2015-01-15 |
| ZA201409076B (en) | 2017-06-28 |
| BR112014030436A2 (pt) | 2017-09-26 |
| KR20150021088A (ko) | 2015-02-27 |
| SG11201408101TA (en) | 2015-01-29 |
| EP3530283A1 (en) | 2019-08-28 |
| WO2013181696A1 (en) | 2013-12-12 |
| JP2015520175A (ja) | 2015-07-16 |
| EP2854837A4 (en) | 2016-06-29 |
| EP2854837A1 (en) | 2015-04-08 |
| AU2013271338B2 (en) | 2018-05-24 |
| IL236092A0 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010676A (es) | Metodos para mejorar la eficacia de una vacuna mediante el uso de un antagonista il-4r. | |
| EA201891022A1 (ru) | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела | |
| CY1122754T1 (el) | Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r | |
| PH12019502424A1 (en) | Compositions and methods for immunotherapy | |
| CY1120622T1 (el) | Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii | |
| MX2017008186A (es) | Anticuerpos humanos para la hemaglutinina de influenza. | |
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
| MX2017007138A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| PH12018501047A1 (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| EP4382164A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| MX390756B (es) | Célula t asesina universal | |
| EA201291105A1 (ru) | Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора | |
| MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| SG10201811190SA (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
| BR112017003332A2 (pt) | uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica | |
| WO2012047267A3 (en) | Polyvalent immunogen | |
| ZA201307069B (en) | Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| NZ702721A (en) | Vaccination with interleukin-4 antagonists | |
| AU2013235442A8 (en) | Stable peptide mimetics of the HIV-1 gp41 pre-hairpin intermediate | |
| MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUN 2018 BY SPRUSON + FERGUSON Effective date: 20170512 |
|
| LAPS | Patent lapsed |